Related Experiment Video
Updated: Jan 8, 2026
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
CSRP1 is a potential therapeutic targets for DLBCL: A computational analysis and in vitro experiments
Wanlu Tian1,2, Fengbo Jin1,2, Yingying Chen1,2
1Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Abstract:
At present, the role of Cysteine and glycine rich protein 1 (CSRP1) in the occurrence and development of diffuse large B lymphoma (DLBCL) has not been reported. We conducted a comprehensive analysis of the potential value of CSRP1 in DLBCL using multiple independent datasets and analytical methods, including differential expression analysis, pathway analysis and immune analysis. Then, cell experiments were used to confirm the regulatory role of CSRP1 in DLBCL. The analysis results show that in DLBCL patients, the expression of CSRP1 is significantly upregulated. In addition, CSRP1 is associated with the cell cycle related pathways and immune microenvironment in DLBCL. Cell experiments confirmed that CSRP1 can significantly regulate the apoptosis and cycle progression of DLBCL cells. In conclusion, CSRP1 may be a potential therapeutic target for DLBCL patients, our research provides a theoretical basis for improving the clinical treatment of DLBCL.
Insights
Cysteine and glycine rich protein 1 (CSRP1) is upregulated in diffuse large B-cell lymphoma (DLBCL), impacting cell cycle and immune microenvironment. CSRP1 may serve as a potential therapeutic target for DLBCL treatment.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- The role of Cysteine and glycine rich protein 1 (CSRP1) in diffuse large B-cell lymphoma (DLBCL) pathogenesis is currently unknown.
- Understanding novel molecular players is crucial for advancing DLBCL treatment strategies.
Purpose of the Study:
- To investigate the expression and functional significance of CSRP1 in DLBCL.
- To evaluate CSRP1 as a potential therapeutic target for DLBCL.
Main Methods:
- Comprehensive analysis of CSRP1 expression using multiple independent DLBCL datasets.
- Differential expression, pathway, and immune microenvironment analyses were performed.
- In vitro cell experiments were conducted to validate CSRP1's regulatory role in DLBCL cell apoptosis and cell cycle progression.
Main Results:
- CSRP1 expression is significantly upregulated in DLBCL patients compared to controls.
- CSRP1 expression correlates with cell cycle-related pathways and the immune microenvironment in DLBCL.
- Experimental validation confirmed CSRP1's significant regulation of DLBCL cell apoptosis and cell cycle progression.
Conclusions:
- CSRP1 plays a significant role in the development and progression of DLBCL.
- CSRP1 represents a potential therapeutic target for improving clinical outcomes in DLBCL patients.
- This research provides a theoretical foundation for novel DLBCL therapeutic strategies targeting CSRP1.
